In this study, although baseline general clinical factors, including HCC status and blood tests, could not predict a deterioration in the liver functional reserve during lenvatinib treatment for HCC, baseline high ANG2 and low VEGF serum levels were closely related to the deterioration of the liver functional reserve at 8 weeks after lenvatinib initiation. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.